Antagonizing Functions of BARD1 and Its Alternatively Spliced Variant BARD1δ in Telomere Stability

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Dec 29

PMID 28030839

Citations 9

Authors

Maxim Pilyugin

Pierre-Alain Andre

Magdalena Ratajska

Alina Kuzniacka

Janusz Limon

Benjamin B Tournier

Julien Colas

Geoff Laurent

Irmgard Irminger-Finger

Affiliations

Soon will be listed here.

Abstract

Previous reports have shown that expression of BARD1δ, a deletion-bearing isoform of BARD1, correlates with tumor aggressiveness and progression. We show that expression of BARD1δ induces cell cycle arrest in vitro and in vivo in non-malignant cells. We investigated the mechanism that leads to proliferation arrest and found that BARD1δ overexpression induced mitotic arrest with chromosome and telomere aberrations in cell cultures, in transgenic mice, and in cells from human breast and ovarian cancer patients with BARD1 mutations. BARD1δ binds more efficiently than BARD1 to telomere binding proteins and causes their depletion from telomeres, leading to telomere and chromosomal instability. While this induces cell cycle arrest, cancer cells lacking G2/M checkpoint controls might continue to proliferate despite the BARD1δ-induced chromosomal instability. These features of BARD1δ may make it a genome permutator and a driver of continuous uncontrolled proliferation of cancer cells.

Citing Articles

Docetaxel response in BRCA1,p53-deficient mammary tumor cells is affected by Huntingtin and BAP1.

Gonzalez-Fernandez M, Perry C, Gerhards N, Francica P, Rottenberg S Proc Natl Acad Sci U S A. 2024; 121(52):e2402849121.

PMID: 39705313 PMC: 11670238. DOI: 10.1073/pnas.2402849121.

A-Z of Epigenetic Readers: Targeting Alternative Splicing and Histone Modification Variants in Cancer.

Mohan N, Dashwood R, Rajendran P Cancers (Basel). 2024; 16(6).

PMID: 38539439 PMC: 10968829. DOI: 10.3390/cancers16061104.

HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms.

Jain A, McCoy M, Coats C, Brown S, Addya S, Pelz C Cancers (Basel). 2022; 14(7).

PMID: 35406624 PMC: 8997573. DOI: 10.3390/cancers14071848.

Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?.

Stempa K, Wokolorczyk D, Kluzniak W, Rogoza-Janiszewska E, Malinska K, Rudnicka H Cancers (Basel). 2021; 13(21).

PMID: 34771627 PMC: 8582358. DOI: 10.3390/cancers13215464.

Expression of BARD1 β Isoform in Selected Pediatric Tumors.

Jasiak A, Krawczynska N, Iliszko M, Czarnota K, Buczkowski K, Stefanowicz J Genes (Basel). 2021; 12(2).

PMID: 33530592 PMC: 7911681. DOI: 10.3390/genes12020168.

References

Laufer M, Nandula S, Modi A, Wang S, Jasin M, Murty V . Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair. J Biol Chem. 2007; 282(47):34325-33. DOI: 10.1074/jbc.M705198200. View

Kleiman F, Manley J . The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. Cell. 2001; 104(5):743-53. DOI: 10.1016/s0092-8674(01)00270-7. View

McCarthy E, Celebi J, Baer R, Ludwig T . Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol Cell Biol. 2003; 23(14):5056-63. PMC: 162231. DOI: 10.1128/MCB.23.14.5056-5063.2003. View

Fabbro M, Rodriguez J, Baer R, Henderson B . BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem. 2002; 277(24):21315-24. DOI: 10.1074/jbc.M200769200. View

Jackson E, Willis N, Mercer K, Bronson R, Crowley D, Montoya R . Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001; 15(24):3243-8. PMC: 312845. DOI: 10.1101/gad.943001. View

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner J, Attiyeh E . Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009; 41(6):718-23. PMC: 2753610. DOI: 10.1038/ng.374. View

Ryser S, Dizin E, Jefford C, Delaval B, Gagos S, Christodoulidou A . Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res. 2009; 69(3):1125-34. DOI: 10.1158/0008-5472.CAN-08-2134. View

Gagos S, Chiourea M, Christodoulidou A, Apostolou E, Raftopoulou C, Deustch S . Pericentromeric instability and spontaneous emergence of human neoacrocentric and minute chromosomes in the alternative pathway of telomere lengthening. Cancer Res. 2008; 68(19):8146-55. DOI: 10.1158/0008-5472.CAN-08-0945. View

Dizin E, Irminger-Finger I . Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1. Int J Biochem Cell Biol. 2010; 42(5):693-700. DOI: 10.1016/j.biocel.2009.12.025. View

10.

Fabbro M, Schuechner S, Au W, Henderson B . BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. Exp Cell Res. 2004; 298(2):661-73. DOI: 10.1016/j.yexcr.2004.05.004. View

11.

Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn F . The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene. 1999; 18(22):3316-23. DOI: 10.1038/sj.onc.1202717. View

12.

Sporn J, Hothorn T, Jung B . BARD1 expression predicts outcome in colon cancer. Clin Cancer Res. 2011; 17(16):5451-62. PMC: 3372413. DOI: 10.1158/1078-0432.CCR-11-0263. View

13.

Irminger-Finger I, Jefford C . Is there more to BARD1 than BRCA1?. Nat Rev Cancer. 2006; 6(5):382-91. DOI: 10.1038/nrc1878. View

14.

Spahn L, Petermann R, Siligan C, Schmid J, Aryee D, Kovar H . Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Res. 2002; 62(16):4583-7. View

15.

Ancelin K, Brun C, Gilson E . Role of the telomeric DNA-binding protein TRF2 in the stability of human chromosome ends. Bioessays. 1999; 20(11):879-83. DOI: 10.1002/(SICI)1521-1878(199811)20:11<879::AID-BIES2>3.0.CO;2-I. View

16.

Wu W, Koike A, Takeshita T, Ohta T . The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div. 2008; 3:1. PMC: 2254412. DOI: 10.1186/1747-1028-3-1. View

17.

Edwards R, Lee M, Tsutakawa S, Williams R, Nazeer I, Kleiman F . The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50. Biochemistry. 2008; 47(44):11446-56. PMC: 2654182. DOI: 10.1021/bi801115g. View

18.

Zimmermann M, Lottersberger F, Buonomo S, Sfeir A, de Lange T . 53BP1 regulates DSB repair using Rif1 to control 5' end resection. Science. 2013; 339(6120):700-4. PMC: 3664841. DOI: 10.1126/science.1231573. View

19.

Martinez P, Blasco M . Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 2011; 11(3):161-76. DOI: 10.1038/nrc3025. View

20.

Sabatier R, Adelaide J, Finetti P, Ferrari A, Huiart L, Sobol H . BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes Chromosomes Cancer. 2010; 49(12):1143-51. DOI: 10.1002/gcc.20822. View